Photo from archive.org
Dalbavancin is a lipoglycopeptide antibiotic active against gram positive organisms with unique weekly dosing. This retrospective study included 37 patients receiving an average of 2.7 weeks of dalbavancin. 9 (24%)… Click to show full abstract
Dalbavancin is a lipoglycopeptide antibiotic active against gram positive organisms with unique weekly dosing. This retrospective study included 37 patients receiving an average of 2.7 weeks of dalbavancin. 9 (24%) patients were readmitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to be $1,495,336 in savings and a mean cost avoidance of $40,414 per patient. Dalbavancin provides a valuable antibiotic option that may minimize health care expenditures.
Keywords:
medical center;
dalbavancin use;
center associated;
use academic;
cost;
academic medical
Journal Title: International journal of antimicrobial agents
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International journal of antimicrobial agents
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!